Reducing the size of infarction with early administration of Metoprolol

10 10 2013

  • Metoprolol reduces a 20% the infarct size
  • This follows the study Metocard-Cnic, Since underway thanks to funds from the Ministry of economy and a grant from the IASB
  • The next step is to assess the reduction of the long-term mortality in patients treated early with this drug

 

The early administration of metoprolol is capable of “reduce the size of infarction in a 20 per cent”, as is the Publisher of Circulation, the journal of the American Association of Cardiology, that just published in its edition of the Spanish study results Metocard-Cnic. Results that could now be extended to all over the world, given the great clinical benefit, low cost of the drug (less than two euros) and universal accessibility of this treatment.

 

Parte del equipo investigador coordinador

Part of the research team coordinator

If so, It would change clinical practice before a patient's as infarction, so far, not receiving routinely this medication before undergoing an angioplasty, recommended intervention to open occluded artery causing infarction.

 

To carry out the analysis of efficacy of metoprolol, drug of the family of the beta-blockers prescribed for the treatment of hypertension and other cardiovascular diseases, researchers have received funding from the Ministry of economy and competitiveness, a competitive Fellowship of the national cardiovascular research centre (CNIC) and the distinction Severo Ochoa obtained by this Center in 2011. “The absence of commercial interest makes difficult to perform independent these drugs in clinical research”, underlines Borja Ibanez, Head of the Group's image in experimental Cardiology of the IASC, and one of the principal investigators of this study.

 

In addition to the low cost of the drug, researchers also highlight the greater return on investment from now, Since the Infracted with less necrotic cardiac muscle are less likely to need an implantable defibrillator, with a cost of over of 200.000 EUR, or require costly revenue for heart failure. “By an expenditure of less than two euros, in the future billions of euros will be saved”, aims Ibáñez. Currently, the same team that carried out the study Metocard-IASB is dealing from an analysis of cost-effectiveness.

 

The study, you have participated community emergency services and a total of seven hospitals in Madrid, Galicia, León and Cantabria had a sample of 270 patients with infarction, those who were randomized to receive metoprolol intravenously or to follow the standard protocol. A week of infarction, discussed the State of the patients from a cardiac magnetic resonance, quantifying all the grams of heart which necrotic had resulted after infarction. Like this, It was found that patients with metoprolol had a very reduced infarct size compared to the control group.

 

Once confirmed the clinical benefit, the researchers are now evaluating what is the mechanism by which this therapy works in patients with infarction. In addition, the IASB and the emergency services are already working also in the logistics of another clinical trial of analysis of the reduction of long-term patients treated with metoprolol early mortality, This time at the international level.

 

Link to the article: here

 

Gacetamedica.com [en línea] Madrid (ESP): gacetamedica.com, 10 de octubre de 2013 [REF. 04 October of 2013] Available on Internet: http://Gazette/articulo.aspx www.gacetamedica.com/?idart = 778304&idcat = 797&Type = 2